Focused On-demand Library for Tyrosine 3-monooxygenase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

Tyrosine 3-hydroxylase

Alternative UPACC:

P07101; B7ZL70; B7ZL73; Q0PWM2; Q0PWM3; Q15585; Q15588; Q15589; Q2M3B4


Tyrosine 3-monooxygenase, also known as Tyrosine 3-hydroxylase, plays a pivotal role in the biosynthesis of catecholamines, including dopamine, noradrenaline, and adrenaline. It catalyzes the conversion of L-tyrosine to L-DOPA, the rate-limiting step in catecholamine synthesis, utilizing tetrahydrobiopterin and molecular oxygen. This enzyme's activity extends beyond tyrosine, as it can also hydroxylate phenylalanine and tryptophan with lower specificity.

Therapeutic significance:

The enzyme's deficiency is linked to Segawa syndrome autosomal recessive, a treatable dystonia due to its favorable response to L-DOPA. Understanding the role of Tyrosine 3-monooxygenase in this condition highlights its therapeutic significance, offering insights into potential treatments for related neurological disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.